Literature DB >> 7970702

Deletion of two regions on chromosome 4 in bladder carcinoma: definition of a critical 750kB region at 4p16.3.

P A Elder1, S M Bell, M A Knowles.   

Abstract

Loss of heterozygosity (LOH) of chromosome 4 has been identified in several human tumours including carcinomas of colorectum, ovary, liver and head and neck. LOH at loci on chromosome 4p has previously been identified in 22% of primary bladder tumours. We have assessed LOH in 178 bladder tumours using a panel of six microsatellite markers. Thirty-four tumours (19%) showed LOH at one or more loci. Twenty-three deletions involved restricted regions of 4p and could be used to define two common regions of deletion. A very small common region between D4S43 and D4S127 (estimated to be approximately 750 kB) was involved in 14/23 (61%) of 4p deletions. A second common region centromeric to D4S174 was deleted in 7/23 (30%) of tumours with deletions. Two tumours (9%) had deletions involving both regions independently. Previous functional studies have demonstrated both a senescence function and a suppressor of tumorigenicity on human chromosome 4. Localisation of the common regions of deletion in bladder tumours provides a starting point for positional cloning of the gene(s) concerned and for more precise comparative functional studies.

Entities:  

Mesh:

Year:  1994        PMID: 7970702

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  RNF4 is a growth inhibitor expressed in germ cells but not in human testicular tumors.

Authors:  R Pero; F Lembo; D Di Vizio; A Boccia; P Chieffi; M Fedele; G M Pierantoni; P Rossi; R Iuliano; M Santoro; G Viglietto; C B Bruni; A Fusco; L Chiariotti
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

2.  Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.

Authors:  Rosário Pinto-Leite; Isabel Carreira; Joana Melo; Susana Isabel Ferreira; Ilda Ribeiro; Jaqueline Ferreira; Marco Filipe; Carina Bernardo; Regina Arantes-Rodrigues; Paula Oliveira; Lúcio Santos
Journal:  Tumour Biol       Date:  2014-01-24

Review 3.  What we could do now: molecular pathology of bladder cancer.

Authors:  M A Knowles
Journal:  Mol Pathol       Date:  2001-08

Review 4.  Genetics of bladder cancer.

Authors:  K K Saran; D Gould; C J Godec; R S Verma
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

5.  Evidence for two candidate tumour suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumour cell lines.

Authors:  A A van Tilborg; L E Groenfeld; T H van der Kwast; E C Zwarthoff
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

6.  Deletion mapping of chromosome 16q in hepatocellular carcinoma.

Authors:  Z Piao; C Park; J J Kim; H Kim
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

7.  MSX1 induces G0/G1 arrest and apoptosis by suppressing Notch signaling and is frequently methylated in cervical cancer.

Authors:  Yujuan Yue; Kun Zhou; Jiachu Li; Shan Jiang; Chunyan Li; Haitao Men
Journal:  Onco Targets Ther       Date:  2018-08-10       Impact factor: 4.147

8.  Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation.

Authors:  P J Hurlin; C Quéva; P J Koskinen; E Steingrímsson; D E Ayer; N G Copeland; N A Jenkins; R N Eisenman
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.